PPARA and Insulin resistance: Our research group previously showed that the orally active AdipoR agonist AdipoRon activates AMPK and PPAR-α pathways22,29, ameliorates insulin resistance and glucose intolerance22,29, and reverses life shortening in obese diabetic mice29.